In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
- PMID: 37210565
- PMCID: PMC10322135
- DOI: 10.1093/oncolo/oyad133
In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
Abstract
This letter to the editor responds to the letter from Su et al, regarding concerns related to immortal time bias that may partially account for recently published study results.
Conflict of interest statement
Zhonglin Hao reported research funding from Bayer Inc. and consulting/advisory relationships with Pfizer and BeiGene. The other authors indicated no financial relationships.
Comment on
-
Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs.Oncologist. 2023 Jan 18;28(1):48-58. doi: 10.1093/oncolo/oyac209. Oncologist. 2023. PMID: 36200844 Free PMC article.
-
Regarding "Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs".Oncologist. 2023 Jul 5;28(7):e588-e589. doi: 10.1093/oncolo/oyad130. Oncologist. 2023. PMID: 37210593 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
